Jin Jin

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.

R. Herbst, C. Fuchs, L. Paz-Ares, 2019, The Lancet. Oncology.

Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open‐Label, Phase I Trial (JVDF)

R. Herbst, D. Ferry, R. Walgren, 2018, The oncologist.

90PDPreviously treated advanced NSCLC cohort from a multi-disease phase 1 study of ramucirumab (R) plus pembrolizumab (P): Efficacy and safety data

R. Herbst, L. Paz-Ares, J. Bendell, 2017 .

Ramucirumab plus pembrolizumab in previously treated advanced or metastatic biliary tract cancer: A multi-disease phase 1 study.

R. Herbst, J. Bendell, D. Ferry, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II Study of Everolimus in Patients with Metastatic Colorectal Adenocarcinoma Previously Treated with Bevacizumab-, Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Based Regimens

C. Fuchs, J. Tabernero, D. Ryan, 2013, Clinical Cancer Research.

Activity of ramucirumab (R) with pembrolizumab (P) by PD-L1 expression in advanced solid tumors: Phase 1a/b study in later lines of therapy.

R. Herbst, C. Fuchs, L. Paz-Ares, 2018 .

Safety and antitumor activity of ramucirumab plus pembrolizumab in treatment naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: Preliminary results from a multi-disease phase I study (JVDF).

R. Herbst, C. Fuchs, D. Ferry, 2018 .

Interim safety and clinical activity in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase I study of ramucirumab (R) plus durvalumab (D).

Y. Bang, Yoon-Koo Kang, Z. Wainberg, 2018 .

Ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A multi-disease phase I study.

R. Herbst, C. Fuchs, J. Bendell, 2017 .